Subject: 10/566063

Please, search fully a compound of formula (1) of claim 1 (in the attached file)
When:
Z= CH_2
r=1
A=phenylene

---

1. (original) A compound of formula (1):



(1)

wherein:

Z is CH or nitrogen;

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:47:22 ON 30 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 30 Sep 2008  VOL 149 ISS 14
FILE LAST UPDATED: 29 Sep 2008  (20080929/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=>
=>

=> d stat que l33
L27             STR
```



VAR G1=C/S
VAR G2=23/AK/25/S/CY
VAR G3=9/13
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
L29 116 SEA FILE=REGISTRY SSS FUL L27
L33 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L29

=> d ibib abs hitstr l33 1-4

L33 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:795762 HCAPLUS Full-text
DOCUMENT NUMBER: 145:211025
TITLE: Thienopyrrole derivatives as glycogen phosphorylase inhibitors and their preparation, pharmaceutical compositions and use for treatment of glycogen phosphorylase mediated diseases
INVENTOR(S): Birch, Alan Martin; Johnstone, Craig; Plowright, Alleyn Thomas; Simpson, Iain; Whittamore, Paul Robert Owen
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 93pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082401	A1	20060810	WO 2006-GB349	20060202

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,

VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2006210719	A1	20060810	AU 2006-210719		20060202
CA 2595835	A1	20060810	CA 2006-2595835		20060202
EP 1848721	A1	20071031	EP 2006-701676		20060202
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR					
JP 2008528667	T	20080731	JP 2007-553691		20060202
NO 2007003710	A	20070831	NO 2007-3710		20070718
IN 2007DN05663	A	20070817	IN 2007-DN5663		20070723
MX 200709438	A	20070816	MX 2007-9438		20070803
KR 2007107108	A	20071106	KR 2007-720315		20070905
CN 101151267	A	20080326	CN 2006-80010515		20070928
PRIORITY APPLN. INFO.:			GB 2005-2465	A	20050205
			GB 2005-2466	A	20050205
			WO 2006-GB349	W	20060202

OTHER SOURCE(S): MARPAT 145:211025

GI



I



II

AB A compound of the formula I or a pharmaceutically-acceptable salt: possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity such as type 2 diabetes. Processes for the manufacture of compds. and pharmaceutical compns. containing them are described. Compds. of formula I wherein Y is CH or N; R4 and R5 together are -S-CR6=CR7- or -CR7=CR6S-; R7 and R7 are independently H, halo, NO2, CN, HO, CH2F, CHF2, CF3, CF3O, carboxy, carbamoyl, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, or C1-4 alkanoyl; n is 0, 1, or 2; each R1 are independently halo, CN, NO2, HO, carboxy, carbamoyl, etc.; Z1 is C1-6 alkylene-CO2H, C3-6 cycloalkylene-CO2, etc.; and their pharmaceutically acceptable salts are claimed. Example compound II was prepared by hydrolysis of tert-Bu [((1R,2R)-2-{[(2-chloro-6H-thieno[2,3-b]pyrrolo-2-yl)carbonyl]amino}-2,3- dihydro-1H-inden-1-yl)methoxy]acetate. All the invention compds. were evaluated for their glycogen phosphorylase inhibitory activity (no data).

IT 905310-22-7P 905310-23-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of thienopyrrole derivs. as glycogen phosphorylase inhibitors useful for treatment of glycogen phosphorylase mediated diseases)
RN 905310-22-7 HCAPLUS
CN 1H-Indene-1-acetic acid, α-(cyclopropylmethyl)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-, (αR,1R,2R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 905310-23-8 HCAPLUS
CN 1H-Indene-1-acetic acid, α-(cyclopropylmethyl)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-, (αS,1R,2R)-(CA INDEX NAME)

Absolute stereochemistry.



IT 905310-14-7P 905310-15-8P 905310-16-9P
905310-17-0P 905310-18-1P 905310-19-2P
905310-20-5P 905310-21-6P 905310-25-0P
905310-27-2P 905310-28-3P 905310-29-4P
905310-30-7P 905310-31-8P 905310-32-9P
905310-33-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of thienopyrrole derivs. as glycogen phosphorylase inhibitors useful for treatment of glycogen phosphorylase mediated diseases)
RN 905310-14-7 HCAPLUS
CN Acetic acid, 2-[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-

yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-15-8 HCAPLUS
CN Acetic acid, 2-[[(1R,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-16-9 HCAPLUS
CN Propanoic acid, 2-[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-17-0 HCAPLUS
CN Propanoic acid, 2-[[(1R,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-18-1 HCAPLUS
CN 1H-Indene-1-propanoic acid, 2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-19-2 HCAPLUS
CN Propanoic acid, 3-[[[(1R,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-20-5 HCAPLUS
CN Propanoic acid, 3-[[[(1R,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-21-6 HCAPLUS
CN 1H-Indene-1-acetic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-25-0 HCAPLUS
CN 1H-Indene-1-acetic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-α-(2-methoxyethyl)-, (αR,1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-27-2 HCAPLUS
CN 1H-Indene-1-acetic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-α-(2-methoxyethyl)-, (αS,1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-28-3 HCAPLUS
CN 1H-Indene-1-acetic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-α-(2-ethoxyethyl)-2,3-dihydro-, (αR,1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-29-4 HCAPLUS
CN 1H-Indene-1-acetic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-α-(2-ethoxyethyl)-2,3-dihydro-, (αS,1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-30-7 HCAPLUS
CN 1H-Indene-1-acetic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-α-(3-methoxypropyl)-, (αR,1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-31-8 HCAPLUS
CN 1H-Indene-1-acetic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-α-(3-methoxypropyl)-, (αS,1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-32-9 HCAPLUS
CN 1H-Indene-1-propanoic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-β-(2-methoxyethyl)-, (βR,1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-33-0 HCAPLUS
CN 1H-Indene-1-propanoic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-β-(2-methoxyethyl)-, (βS,1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 845268-34-0P 845268-35-1P 845268-40-8P
845269-11-6P 845269-12-7P 845269-16-1P
905310-36-3P 905310-37-4P 905310-38-5P
905310-39-6P 905310-40-9P 905310-41-0P
905310-42-1P 905310-43-2P 905310-44-3P
905310-48-7P 905310-51-2P 905310-52-3P
905310-58-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thienopyrrole derivs. as glycogen phosphorylase inhibitors useful for treatment of glycogen phosphorylase mediated diseases)
RN 845268-34-0 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-(hydroxymethyl)-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-35-1 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-(hydroxymethyl)-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-40-8 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[[(methylsulfonyl)oxy]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845269-11-6 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845269-12-7 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845269-16-1 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[[(methylsulfonyl)oxy]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-36-3 HCAPLUS
CN Acetic acid, 2-[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-37-4 HCAPLUS
CN Acetic acid, 2-[[(1R,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methoxy]-, 1,1-dimethylethyl

ester (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-38-5 HCAPLUS
CN Propanoic acid, 2-[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-39-6 HCAPLUS
CN Propanoic acid, 2-[[(1R,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-40-9 HCAPLUS
CN 1H-Indene-1-propanoic acid, 2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-, ethyl ester, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-41-0 HCAPLUS
CN Propanedioic acid, 2-[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methyl]-, 1,3-diethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-42-1 HCAPLUS
CN Propanoic acid, 3-[[[(1R,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methyl]thio]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-43-2 HCAPLUS
CN 1H-Indene-1-acetic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-, methyl ester, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-44-3 HCAPLUS
CN 1H-Indene-1-acetic acid, α-(cyclopropylmethyl)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-, methyl ester, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-48-7 HCAPLUS
CN Propanedioic acid, 2-[(1S,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-(2-methoxyethyl)-, 1,3-dimethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-51-2 HCAPLUS
CN Propanedioic acid, 2-[(1S,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-(2-ethoxyethyl)-, 1,3-dimethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-52-3 HCAPLUS
CN Propanedioic acid, 2-[(1S,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]-2-(3-methoxypropyl)-, 1,3-dimethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 905310-58-9 HCAPLUS
CN 1H-Indene-1-propanoic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-β-(2-methoxyethyl)-, methyl ester, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:216669 HCAPLUS Full-text
DOCUMENT NUMBER: 142:297985
TITLE: Preparation of thienopyrrole carboxamides as glycogen phosphorylase inhibitors
INVENTOR(S): Bennett, Stuart Norman Lile; Simpson, Iain

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020986	A1	20050310	WO 2004-GB3622	20040825

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-20241 A 20030829
GB 2003-24788 A 20031024
OTHER SOURCE(S): CASREACT 142:297985; MARPAT 142:297985
GI



I



II

AB Title compds. represented by the formula I [wherein A = phenylene or heteroarylene; n = 0-2; R1 = independently halo, NO2, CN, carbamoyl, etc.; R2R3 = heterocyclic ring; R4R5 = -SC(R6):C(R7)- or -C(R7):C(R6)S-; R6, R7 = independently H, halo, OH, carboxy, etc.; and pharmaceutically acceptable salts or prodrugs thereof] were prepared as glycogen phosphorylase inhibitors (no data). For example, II was given in a multi-step synthesis starting from the reaction of Me 2-chlorothiophene-3- carboxaldehyde with Me azidoacetate. I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of disease states associated with increased glycogen phosphorylase activity (no data).

IT 847658-03-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thienopyrrole carboxamides as glycogen phosphorylase inhibitors)

RN 847658-03-1 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(5S)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 847657-97-0P 847657-98-1P 847657-99-2P
847658-01-9P 847658-02-0P 847658-04-2P
847658-05-3P 847658-06-4P 847658-07-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienopyrrole carboxamides as glycogen phosphorylase inhibitors)

RN 847657-97-0 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-(2-oxo-3-oxazolidinyl)-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847657-98-1 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(5S)-5-[(methylsulfinyl)methyl]-2-oxo-3-oxazolidinyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847657-99-2 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(5S)-5-[(methylsulfonyl)methyl]-2-oxo-3-oxazolidinyl]-1H-inden-2-yl]-(CA INDEX NAME)

Absolute stereochemistry.



RN 847658-01-9 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[(5R)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,3-dihydro-1H-inden-2-yl]-2-chloro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 847658-00-8
CMF C20 H19 Cl N4 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 847658-02-0 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(5R)-5-(1H-imidazol-1-ylmethyl)-2-oxo-3-oxazolidinyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847658-04-2 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(3S)-3-hydroxy-2-oxo-1-pyrrolidinyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847658-05-3 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-(3-hydroxy-2-oxo-1-pyrrolidinyl)-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847658-06-4 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(3R)-3-hydroxy-2-oxo-1-pyrrolidinyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847658-07-5 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(3S)-3-hydroxy-2-oxo-1-pyrrolidinyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 847658-11-1P 847658-12-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thienopyrrole carboxamides as glycogen phosphorylase inhibitors)
RN 847658-11-1 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(5S)-5-[(methylthio)methyl]-2-oxo-3-oxazolidinyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847658-12-2 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(5S)-5-[[(methylsulfonyl)oxy]methyl]-2-oxo-3-oxazolidinyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:136553 HCAPLUS Full-text
DOCUMENT NUMBER: 142:240303
TITLE: Preparation of thienopyrrole amide derivatives as glycogen phosphorylase inhibitors
INVENTOR(S): Birch, Alan Martin; Bennett, Stuart Norman Lile; Campbell, Andrew Duncan; Simpson, Iain; Whittamore, Paul Robert Owen; Whalley, David Paul; Godfrey, Linda
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013981	A1	20050217	WO 2004-GB3345	20040804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1658069	A1	20060524	EP 2004-743648		20040804
EP 1658069	B1	20080730			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
JP 2007501779	T	20070201	JP 2006-522397		20040804
AT 402696	T	20080815	AT 2004-743648		20040804
US 20080064691	A1	20080313	US 2006-566063		20060126
PRIORITY APPLN. INFO.:			GB 2003-18463	A	20030807
			WO 2004-GB3345	W	20040804

OTHER SOURCE(S): CASREACT 142:240303; MARPAT 142:240303

GI



I

II

AB Title compds. represented by the formula I [wherein A = phenylene or heteroarylene; n = 0-2, r = 1 or 2; R1 = independently halo, NO2, CN, carbamoyl, etc.; R4, R5 together are either -SC(R6):C(R7)- or -C(R7):C(R6)S-; R6, R7 = independently H, halo, NO2, CF3, alkoxy, etc.; and pharmaceutically acceptable salts or prodrugs thereof] were prepared as glycogen phosphorylase inhibitors (no data). For example, II was given in a multi-step synthesis starting from Me 2-oxoindane-1-carboxylate. I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of disease states associated with increased glycogen phosphorylase activity.

IT 845268-31-7P 845268-32-8P 845268-34-0P
845268-35-1P 845268-40-8P 845268-44-2P
845268-47-5P 845268-53-3P 845268-54-4P
845268-56-6P 845268-60-2P 845268-64-6P
845268-65-7P 845268-66-8P 845268-67-9P
845268-69-1P 845268-71-5P 845268-75-9P
845268-76-0P 845268-79-3P 845268-82-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thienopyrrole amide derivs. as glycogen phosphorylase inhibitors)

RN 845268-31-7 HCAPLUS

CN 1H-Indene-1-carboxylic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-, methyl ester, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-32-8 HCAPLUS
CN 1H-Indene-1-carboxylic acid, 2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-34-0 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-(hydroxymethyl)-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-35-1 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-(hydroxymethyl)-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-40-8 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[[(methylsulfonyl)oxy]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-44-2 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(methylthio)methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-47-5 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1S,2R)-2,3-dihydro-1-(4-thiomorpholinylmethyl)-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-53-3 HCAPLUS
CN Acetic acid, 2-[[(1R,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-54-4 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[[2-(dimethylamino)-2-oxoethyl]thio]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-56-6 HCAPLUS
CN Acetic acid, 2-[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]thio]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 845268-60-2 HCAPLUS
CN 1H-Indene-1-acetic acid, 2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 845268-64-6 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[[(2-hydroxyethyl)thio]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-65-7 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[[(3-hydroxypropyl)thio]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-66-8 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[[(2,3-dihydroxypropyl)thio]methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-67-9 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[[[2-(acetylamino)ethyl]thio]methyl]-2,3-dihydro-1H-inden-2-yl]-2-chloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-69-1 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[[[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]thio]methyl]-2,3-dihydro-1H-inden-2-yl]-

(CA INDEX NAME)

Absolute stereochemistry.



RN 845268-71-5 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[[(2-hydroxyethyl)sulfonyl]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-75-9 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[[[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]sulfinyl]methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-76-0 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[[[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]sulfonyl]methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-79-3 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[(ethenylsulfonyl)methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-82-8 HCAPLUS
CN Glycine, N-[[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 845268-33-9P 845268-36-2P 845268-37-3P
845268-38-4P 845268-39-5P 845268-41-9P
845268-42-0P 845268-43-1P 845268-45-3P
845268-46-4P 845268-48-6P 845268-49-7P
845268-50-0P 845268-51-1P 845268-52-2P
845268-55-5P 845268-57-7P 845268-58-8P
845268-59-9P 845268-61-3P 845268-62-4P
845268-63-5P 845268-68-0P 845268-70-4P
845268-72-6P 845268-73-7P 845268-74-8P
845268-77-1P 845268-78-2P 845268-80-6P
845268-81-7P 845268-83-9P 845268-84-0P
845268-85-1P 845268-87-3P 845268-89-5P
845268-91-9P 845268-92-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienopyrrole amide derivs. as glycogen phosphorylase inhibitors)

RN 845268-33-9 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-(aminocarbonyl)-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-36-2 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[[(3S,4R)-3,4-dihydroxy-1-pyrrolidinyl]carbonyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-37-3 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[[(2,3-dihydroxypropyl)amino]carbonyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-38-4 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[[(2-hydroxyethyl)amino]carbonyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-39-5 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[[(2-amino-2-oxoethyl)amino]carbonyl]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-41-9 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1S,2R)-1-[(acetylamino)methyl]-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-42-0 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2R)-1-[(formylamino)methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-43-1 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1S,2R)-2,3-dihydro-1-[[(2-hydroxyacetyl)amino]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-45-3 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(methylsulfinyl)methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-46-4 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(methylsulfonyl)methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-48-6 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1S,2R)-2,3-dihydro-1-[(1-oxido-4-thiomorpholinyl)methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-49-7 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1S,2R)-1-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-50-0 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-(methylthio)-1H-inden-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 845268-51-1 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-(1H-imidazol-2-ylthio)-1H-inden-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 845268-52-2 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]-1H-inden-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 845268-55-5 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[[2-(dimethylamino)-2-oxoethyl]sulfonyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-57-7 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[[2-(dimethylamino)-2-oxoethyl]thio]-2,3-dihydro-1H-inden-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 845268-58-8 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(2-hydroxyethyl)thio]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-59-9 HCAPLUS
CN 1H-Indene-1-acetic acid, 2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-, methyl ester, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 845268-61-3 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[2-(dimethylamino)-2-oxoethyl]-2,3-dihydro-1H-inden-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 845268-62-4 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[2-(4-morpholinyl)-2-oxoethyl]-1H-inden-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 845268-63-5 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[2-[(2-hydroxyethyl)amino]-2-oxoethyl]-1H-inden-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 845268-68-0 HCAPLUS
CN Acetic acid, 2-[[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methyl]thio]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-70-4 HCAPLUS
CN Ethanethioic acid, S-[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methyl] ester (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-72-6 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[[(3-hydroxypropyl)sulfonyl]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-73-7 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[[(2,3-dihydroxypropyl)sulfonyl]methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-74-8 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[(1R,2R)-1-[[[2-(acetylamino)ethyl]sulfonyl]methyl]-2,3-dihydro-1H-inden-2-yl]-2-chloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-77-1 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[[[(2S)-2,3-dihydroxypropyl]sulfonyl]methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-78-2 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[[[(2S)-2,3-dihydroxypropyl]sulfinyl]methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-80-6 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[[[2-(1H-imidazol-1-yl)ethyl]sulfonyl]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-81-7 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[[[(2-hydroxyethyl)amino]sulfonyl]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-83-9 HCAPLUS
CN Glycine, N-[[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]methyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-84-0 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[[[(2-hydroxyethyl)amino]sulfonyl]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-85-1 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[[(propylamino)sulfonyl]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-87-3 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-1-[(4-morpholinylsulfonyl)methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-89-5 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[[[(2,3-dihydroxypropyl)amino]sulfonyl]methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-91-9 HCAPLUS
CN Propanoic acid, 2-[[(1R,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845268-92-0 HCAPLUS
CN Propanoic acid, 2-[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



IT 845269-11-6P 845269-12-7P 845269-14-9P
845269-16-1P 845269-28-5P 845269-29-6P
845269-64-9P 845269-66-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thienopyrrole amide derivs. as glycogen phosphorylase inhibitors)
RN 845269-11-6 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1R,2R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845269-12-7 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,3-dihydro-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845269-14-9 HCAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, N-[(1S,2R)-1-(aminomethyl)-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 845269-16-1 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-1-[[(methylsulfonyl)oxy]methyl]-1H-inden-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 845269-28-5 HCAPLUS
CN Acetic acid, 2-[[(1R,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]thio]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 845269-29-6 HCAPLUS
CN Acetic acid, 2-[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]thio]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 845269-64-9 HCAPLUS
CN Propanoic acid, 2-[[(1R,2R)-2-[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]thio]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 845269-66-1 HCAPLUS
CN Propanoic acid, 2-[[(1R,2R)-2-[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1H-inden-1-yl]thio]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:353446 HCAPLUS Full-text
DOCUMENT NUMBER: 136:355151
TITLE: Preparation of (heteroarylcarbonylamino)bicycloheptane alkenoic acid and -alkanoic acid derivatives as prostaglandin D2 (PGD2) receptor antagonists and pharmaceutical compositions containing them
INVENTOR(S): Tanimoto, Norihiko; Hiramatsu, Yoshiharu; Honma, Tsunetoshi; Inagaki, Masanao
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036583	A1	20020510	WO 2001-JP9435	20011026

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2001096013 A5 20020515 AU 2001-96013 20011026
EP 1338594 A1 20030827 EP 2001-976842 20011026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 20040054003 A1 20040318 US 2003-399605 20030418
PRIORITY APPLN. INFO.: JP 2000-334383 A 20001101
WO 2001-JP9435 W 20011026
OTHER SOURCE(S): MARPAT 136:355151
GI



AB Bicycloheptane amide derivs. of the general formula (I; wherein Y is a bicyclic ring Q, Q1, or Q2; R1 is optionally substituted heteroaryl; R2 is hydrogen or alkyl; R3 is CH2CH2CH2CH2CH:CHCO2R4, CH2CH2CH2CH2-X1-CH2CO2R4, CH2CH:CHCH2-X1-CH2CO2R4, or CH2CH2CH2CH2CO2R4; R4 is hydrogen or alkyl; and X1 is O or S), which are metabolically stable and exhibit PGD2 receptor antagonism, are prepared The title compound (II) in vitro inhibited the binding of [3H]PGD2 to human blood platelet membrane with IC50 of 0.0035 μmol/L and suppressed the PGD2-induced increase in cAMP level in human platelet rich plasma. These compds. are useful for the treatment of rhinostenosis (stuffy nose), allergic conjunctivitis, and allergic rhinitis.

IT 420803-98-1P 420803-99-2P 420804-14-4P
420804-15-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (heteroarylcarbonylamino)bicycloheptanealkenoic acid and -alkanoic acid derivs. as prostaglandin D2 (PGD2) receptor antagonists for therapeutic agents)

RN 420803-98-1 HCAPLUS

CN 2-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[(4H-thieno[3,2-b]pyrrol-5-ylcarbonyl)amino]bicyclo[2.2.1]hept-2-yl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 420803-99-2 HCAPLUS
CN 2-Heptenoic acid, 7-[(1R,2S,3S,4S)-3-[(6H-thieno[2,3-b]pyrrol-5-ylcarbonyl)amino]bicyclo[2.2.1]hept-2-yl]-, (2E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 420804-14-4 HCAPLUS
CN Acetic acid, 2-[4-[(1R,2S,3S,4S)-3-[(4H-thieno[3,2-b]pyrrol-5-ylcarbonyl)amino]bicyclo[2.2.1]hept-2-yl]butoxy]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 420804-15-5 HCAPLUS
CN Acetic acid, 2-[4-[(1R,2S,3S,4S)-3-[(6H-thieno[2,3-b]pyrrol-5-ylcarbonyl)amino]bicyclo[2.2.1]hept-2-yl]butoxy]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=>
=> => D STAT QUE L47
L27             STR
```










```
VAR G1=C/S
VAR G2=23/AK/25/S/CY
VAR G3=9/13
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  22

STEREO ATTRIBUTES: NONE
L29         116 SEA FILE=REGISTRY SSS FUL L27
L33           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L29
L34          48 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("BIRCH ALAN"/AU OR "BIRCH
                ALAN M"/AU OR "BIRCH ALAN MARTIN"/AU) OR BIRCH A/AU
L35         165 SEA FILE=HCAPLUS ABB=ON  PLU=ON  BENNETT S/AU OR BENNETT S
                L/AU OR BENNETT S N/AU OR BENNETT STUART/AU OR BENNETT STUART
                N?/AU OR BENNETT NORMAN/AU OR BENNETT NORMAN L/AU OR STUART
                N/AU OR STUART NORMAN/AU
L36         144 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "CAMPBELL ANDREW"/AU OR
                "CAMPBELL ANDREW D"/AU OR "CAMPBELL ANDREW DUNCAN"/AU OR
                CAMPBELL A D/AU
L37         182 SEA FILE=HCAPLUS ABB=ON  PLU=ON  SIMPSON I/AU OR SIMPSON I
                ?/AU OR "SIMPSON IAIN"/AU OR SIMPSON IAIN ?/AU
L38          31 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("WHITTAMORE PAUL"/AU OR
                "WHITTAMORE PAUL R"/AU OR "WHITTAMORE PAUL R O"/AU OR "WHITTAMO
                RE PAUL ROBERT OWEN"/AU)
L39          12 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "WHALLEY D"/AU OR ("WHALLEY
                DAVE P"/AU OR "WHALLEY DAVID"/AU) OR ("WHALLEY DAVID P"/AU OR
                "WHALLEY DAVID PAUL"/AU)
L40          47 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("GODFREY LINDA"/AU OR
                "GODFREY LINDA V"/AU) OR GODFREY L/AU OR GODFREY L ?/AU
L41          10 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L34 AND (L35 OR L36 OR L37 OR
                L38 OR L39 OR L40)
L42           9 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L35 AND (L36 OR L37 OR L38 OR
                L39 OR L40)
L43           1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L36 AND (L37 OR L38 OR L39 OR
                L40)
L44           9 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L37 AND (L38 OR L39 OR L40)
L45           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L38 AND (L39 OR L40)
L46           2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L39 AND L40
```

L47 13 SEA FILE=HCAPLUS ABB=ON PLU=ON (L41 OR L42 OR L43 OR L44 OR L45 OR L46) NOT L33

=>
=> D IBIB ABS HITSTR L47 1-13

L47 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1419924 HCAPLUS Full-text
DOCUMENT NUMBER: 148:55034
TITLE: Preparation of aminooxazolecarboxamides as acyl CoA:diacylglycerol acyltransferase (DGAT1) inhibitors for the treatment of diabetes and obesity.
INVENTOR(S): Birch, Alan Martin; Davies, Robert; Whalley, David Paul
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 61pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007141538	A1	20071213	WO 2007-GB2119	20070608

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2006-11507 A 20060610
OTHER SOURCE(S): MARPAT 148:55034
GI



I

AB Title compds. [I; R1 = (substituted) aryl, heteroaryl; T = N, CH, CMe; Y = bond, (CR40R41)s, X6(CR40R41)t; R40, R41 = H, alkyl, OH, halo, cyano, etc.; s, t = 0-6; X6 = CO, CO2, O, S, SO, SO2, imino, etc.; R2 = (substituted) aryl, cycloalkyl, heterocyclyl], were prepared Thus, 2-[(2,4,5-trifluorophenyl)amino]oxazole-4-carboxylic acid (preparation given), Me trans-2-[4-(4-aminophenyl)cyclohexyl]acetate (preparation given), ECAC, and HOBt

were stirred together in dimethylacetamide at room temperature for 100 min. to give Me trans-2-[4-[4-[[2-[(2,4,5-trifluorophenyl)amino]oxazole-4-carbonyl]amino]phenyl]cyclohexyl]acetate. The 3,4-difluorophenyl analog of the above inhibited DGAT1 with IC50 = 32 μM.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:79573 HCAPLUS Full-text
DOCUMENT NUMBER: 146:197770
TITLE: Development of potent, orally active 1-substituted-3,4-dihydro-2-quinolone glycogen phosphorylase inhibitors
AUTHOR(S): Birch, Alan M.; Kenny, Peter W.; Oikonomakos, Nikos G.; Otterbein, Ludovic; Schofield, Paul; Whittamore, Paul R. O.; Whalley, Dave P.
CORPORATE SOURCE: AstraZeneca, Cheshire, SK10 4TG, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(2), 394-399
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:197770
AB A series of substituted 3,4-dihydro-2-quinolone glycogen phosphorylase inhibitors, which have potential as antidiabetic agents, is described. Initial members of the series showed good enzyme inhibitory potency but poor phys. properties. Optimization of the 1-substituent led to 2,3-dihydroxypropyl compds. which showed good in vitro potency and improved phys. properties, together with good DMPK profiles and acute in vivo efficacy in a rat model. X-ray crystallog. data are presented, showing an unexpected variety of binding orientations at the dimer interface site.
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1001125 HCAPLUS Full-text
DOCUMENT NUMBER: 146:215
TITLE: Novel thienopyrrole glycogen phosphorylase inhibitors: Synthesis, in vitro SAR and crystallographic studies
AUTHOR(S): Whittamore, Paul R. O.; Addie, Matthew S.; Bennett, Stuart N. L.; Birch, Alan M.; Butters, Michael; Godfrey, Linda; Kenny, Peter W.; Morley, Andrew D.; Murray, Paul M.; Oikonomakos, Nikos G.; Otterbein, Ludovic R.; Pannifer, Andrew D.; Parker, Jeremy S.; Readman, Kristy; Siedlecki, Pawel S.; Schofield, Paul; Stocker, Andy; Taylor, Melvyn J.; Townsend, Linda A.; Whalley, David P.; Whitehouse, Jennifer
CORPORATE SOURCE: AstraZeneca, Cheshire, SK10 4TG, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(21), 5567-5571
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:215
AB Two series of novel thienopyrrole inhibitors of recombinant human liver glycogen phosphorylase a (GPa) which are effective in reducing glucose output

from rat hepatocytes are described. Representative compds. have been shown to bind at the dimer interface site of the rabbit muscle enzyme by X-ray crystallog.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:791885 HCAPLUS Full-text
DOCUMENT NUMBER: 145:210884
TITLE: Preparation of indolylcarbonylaminoindane derivatives with glycogen phosphorylase inhibitory activity
INVENTOR(S): Birch, Alan Martin; Johnstone, Craig; Plowright, Alleyn Thomas; Simpson, Iain; Whittamore, Paul Robert Owen
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 71pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082400	A1	20060810	WO 2006-GB347	20060202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1848693	A1	20071031	EP 2006-709600	20060202
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008528666	T	20080731	JP 2007-553690	20060202
IN 2007DN05662	A	20070817	IN 2007-DN5662	20070723
CN 101151245	A	20080326	CN 2006-80010225	20070928

PRIORITY APPLN. INFO.:
GB 2005-2467 A 20050205
GB 2005-2468 A 20050205
WO 2006-GB347 W 20060202

OTHER SOURCE(S): CASREACT 145:210884; MARPAT 145:210884
GI



I



II

AB Title compds. I [R1 = halo, NO2, CN, OH, etc.; R4 = halo, OH, F3C, etc.; m = 0-2; n = 0-2; when n = 2 the two R1 groups may together form (un)substituted cyclic or heterocyclic ring; Z1 = alkylenecarboxylic acid, cycloalkylenecarboxylic acid, alkoxyalkylcarboxylic acid, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as possessing glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Thus, e.g., II was prepared by amidation of tert-Bu {[(1R,2R)-2-amino-2,3-dihydro-1H-inden-1-yl]methoxy}acetate (preparation given) with 5-chloroindole-2-carboxylic acid followed by deprotection. In glycogen phosphorylase inhibition assays, I were found to typically possess IC50 values in the range 100μM to 1nM. Processes for the manufacture of compds. and pharmaceutical compns. containing them are described.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:308290 HCAPLUS Full-text
DOCUMENT NUMBER: 143:7658
TITLE: Expedient syntheses of sulfonylhydantoins and two six-membered analogs
AUTHOR(S): Campbell, Andrew D.; Birch, Alan M.
CORPORATE SOURCE: Research and Development, AstraZeneca, Cheshire, SK10 4TG, UK
SOURCE: Synlett (2005), (5), 834-838
CODEN: SYNLES; ISSN: 0936-5214
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:7658
GI



I



II



III

AB A range of α-amino esters can be turned into sulfonylhydantoins in a single, atom-economic step using sulfamide and DBU. E.g., reaction of BnNHCH2CO2Et with sulfamide and DBU gave 65% sulfonylhydantoin I. This procedure obviates the need for a three- or four-step sequence utilized by traditional procedures. Two new six-membered analogs [5-aryl-1,2,6- thiadiazinan-3-one 1,1-dioxides and 5-aryl-1,2-thiazinan-3-one 1,1-dioxides], e.g. II and III, have also been prepared utilizing novel synthetic protocols.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:216670 HCAPLUS Full-text
DOCUMENT NUMBER: 142:298003
TITLE: Preparation of thieno[3,2-b]pyrrole amide derivatives as glycogen phosphorylase inhibitors
INVENTOR(S): Birch, Alan Martin; Simpson, Iain; Stocker, Andrew; Whittamore, Paul Robert Owen
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020987	A1	20050310	WO 2004-GB3648	20040827

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG
PRIORITY APPLN. INFO.: GB 2003-20422 A 20030830
OTHER SOURCE(S): CASREACT 142:298003; MARPAT 142:298003
GI



I



II

AB Title compds. represented by the formula I [wherein B = (un)substituted pyrrolyl-2-carbonyl or indolyl-2-carbonyl; R1 = independently halo, nitro, carbamoyl, alkanoyloxy, etc., R2 = H, (hydroxy)alkyl, alkylcarbonylaminoalkyl, etc.; A = pyridylene ring; n = 0 or 1; and pharmaceutically acceptable salts or prodrugs thereof] were prepared as glycogen phosphorylase inhibitors. For example, II was given in a multi-step synthesis starting from 4,5-dichlorothiophene-2-carboxaldehyde. II showed thermodn. solubility (16.2 μM) and plasma-protein binding activity with 0.06 μM. Thus, I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinemia, hyperglucagonemia, cardiac ischemia or obesity in a warm-blooded animal, such as man (no data).
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:216668 HCAPLUS Full-text
DOCUMENT NUMBER: 142:297984
TITLE: Preparation of indole-2-carboxamide derivatives as glycogen phosphorylase inhibitors
INVENTOR(S): Bennett, Stuart Norman Lile; Simpson, Iain
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020985	A1	20050310	WO 2004-GB3620	20040825

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-20242 A 20030829
GB 2004-1800 A 20040128

OTHER SOURCE(S): CASREACT 142:297984; MARPAT 142:297984

GI



I



II

AB Title compds. represented by the formula I [wherein A = phenylene or heteroarylene; n = 0-2; m = 0-2; R1 = independently halo, NO2, CN, carbamoyl, etc.; R2R3 = (un)substituted heterocyclic ring; R4 = independently halo, OH, carboxy, etc.; with a proviso; and pharmaceutically acceptable salts or prodrugs thereof] were prepared as glycogen phosphorylase inhibitors (no data). For example, II was given in a multi-step synthesis starting from 5-chloroindole-2-carboxylic acid. I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of disease states associated with increased glycogen phosphorylase activity (no data).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:182625 HCAPLUS Full-text
DOCUMENT NUMBER: 142:261398
TITLE: Preparation of indole-2-carboxamide derivatives as glycogen phosphorylase inhibitors
INVENTOR(S): Bennett, Stuart Norman Lile; Simpson, Iain; Whittamore, Paul Robert Owen
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019172	A1	20050303	WO 2004-GB3552	20040818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1660448	A1	20060531	EP 2004-801875	20040818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007503421	T	20070222	JP 2006-524409	20040818
US 20060199966	A1	20060907	US 2006-567798	20060209
PRIORITY APPLN. INFO.:			GB 2003-19690 A	20030822
			WO 2004-GB3552 W	20040818

OTHER SOURCE(S): CASREACT 142:261398; MARPAT 142:261398

GI



I



II

AB Title compds. represented by the formula I [wherein A = phenylene or heteroarylene; n = 0-2; m = 0-2; R1 = independently halo, NO2, CN, carbamoyl, etc.; R2, R3 = independently (halo)alkyl, CF3, hydroxyalkyl, etc.; R4 = independently halo, OH, carboxy, etc.; and pharmaceutically acceptable salts or prodrugs thereof] were prepared as glycogen phosphorylase inhibitors. For example, II•HCl was given in a multi-step synthesis starting from 5-chloroindole-2-carboxylic acid. II showed 173 μM thermodn. solubility and plasma protein binding activity with Ki value of 0.5 μM. Thus, I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of disease states associated with increased glycogen phosphorylase activity.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:177891 HCAPLUS Full-text
DOCUMENT NUMBER: 142:261397
TITLE: Preparation of thieno[2,3-b]pyrrole-5-carboxamide derivatives as glycogen phosphorylase inhibitors
INVENTOR(S): Bennett, Stuart Norman Lile; Simpson, Iain; Whittamore, Paul Robert Owen
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005018637	A1	20050303	WO 2004-GB3546		20040818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1656136	A1	20060517	EP 2004-768106		20040818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
JP 2007503420	T	20070222	JP 2006-524408		20040818
US 20060264494	A1	20061123	US 2006-567801		20060209
PRIORITY APPLN. INFO.:			GB 2003-19759	A	20030822
			WO 2004-GB3546	W	20040818

OTHER SOURCE(S): CASREACT 142:261397; MARPAT 142:261397
GI



I



II

AB Title compds. represented by the formula I [wherein A = phenylene or heteroarylene; n = 0-2; R1 = independently halo, NO2, CN, carbamoyl, etc.; R2, R3 = independently (halo)alkyl, CF3, hydroxyalkyl, etc.; R4R5 = -SC(R6):C(R7)- or -C(R7):C(R6)S-; R6, R7 = independently H, halo, OH, carboxy, etc.; and pharmaceutically acceptable salts or prodrugs thereof] were prepared as glycogen phosphorylase inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of Me 2-chlorothiophene-3-carboxaldehyde with Me azidoacetate. II showed plasma-protein binding activity with an IC50 value of 0.07 μM. Thus, I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of disease states associated with increased glycogen phosphorylase activity.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:136547 HCAPLUS Full-text
DOCUMENT NUMBER: 142:240308
TITLE: Preparation of indole-2-carboxamide derivatives as glycogen phosphorylase inhibitors
INVENTOR(S): Birch, Alan Martin; Bennett, Stuart Norman Lile; Godfrey, Linda; Simpson, Iain; Whittamore, Paul Robert Owen
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005013975	A1	20050217	WO 2004-GB3364		20040804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1658067	A1	20060524	EP 2004-743655		20040804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
JP 2007501780	T	20070201	JP 2006-522398		20040804
US 20060211760	A1	20060921	US 2006-566068		20060126
PRIORITY APPLN. INFO.:			GB 2003-18464	A	20030807
			WO 2004-GB3364	W	20040804

OTHER SOURCE(S): CASREACT 142:240308; MARPAT 142:240308
GI



I

II

AB Title compds. represented by the formula I [wherein A = phenylene or heteroarylene; n = 0-2; m = 0-2; R1 = independently halo, NO2, CN, carbamoyl, etc.; R4 = independently halo, OH, carboxy, etc.; p = 1 or 2; and pharmaceutically acceptable salts or prodrugs thereof] were prepared as glycogen phosphorylase inhibitors (no data). For example, II was given in a multi-step synthesis starting from Me 2-oxoindane-1-carboxylate. Thus, I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of disease states associated with increased glycogen phosphorylase activity.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:719489 HCAPLUS Full-text
DOCUMENT NUMBER: 139:261278
TITLE: Preparation of heterocyclic amides as inhibitors of glycogen phosphorylase
INVENTOR(S): Birch, Alan Martin; Morley, Andrew David; Stocker, Andrew; Whittamore, Paul Robert Owen
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074532	A1	20030912	WO 2003-GB877	20030304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477667	A1	20030912	CA 2003-2477667	20030304
AU 2003214377	A1	20030916	AU 2003-214377	20030304

BR 2003008146	A	20041207	BR 2003-8146	20030304
EP 1483270	A1	20041208	EP 2003-709947	20030304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1653070	A	20050810	CN 2003-810214	20030304
CN 100384852	C	20080430		
JP 2005526058	T	20050902	JP 2003-573000	20030304
NZ 534990	A	20060224	NZ 2003-534990	20030304
IN 2004DN02389	A	20070406	IN 2004-DN2389	20040817
ZA 2004006679	A	20050118	ZA 2004-6679	20040823
US 20050131015	A1	20050616	US 2004-506741	20040903
US 7129249	B2	20061031		
MX 2004PA08614	A	20041206	MX 2004-PA8614	20040906
NO 2004003852	A	20040914	NO 2004-3852	20040914
US 20070043069	A1	20070222	US 2006-463144	20060808
US 7276517	B2	20071002		

PRIORITY APPLN. INFO.:	GB 2002-5165	A	20020306
	WO 2003-GB877	W	20030304
	US 2004-506741	A1	20040903

OTHER SOURCE(S): MARPAT 139:261278

GI



I



II

AB The title compds. [I; X = N, CH; R4 and R5 together are either SCR6:CR7 or CR7:CR6S; R6, R7 = H, halo, alkyl, etc.; A = phenylene or heteroarylene; n = 0-2; R1 = halo, NO2, CN, OH, CO2H, etc.; R2 = H, OH, CO2H; R3 = H, OH, aryl, heterocyclyl, etc.] which possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity such as diabetes type II, were prepared Thus, amidation of 5-carboxy-2-chloro-6H-thieno[2,3- b]pyrrole with Me (3-amino-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate (prepns. given) in the presence of HOBT and EDCI in DMF afforded 76% II. The compds. I showed IC50 values in the range 100μM to 1nM against hrl glycogen phosphorylase a (hrl GPa). Pharmaceutical composition comprising the compound I was claimed.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:719488 HCAPLUS Full-text

DOCUMENT NUMBER: 139:246010

TITLE: Preparation of heterocyclic amide derivatives having

glycogen phosphorylase inhibitory activity

INVENTOR(S): Whittamore, Paul Robert Owen; Bennett, Stuart Norman Lile; Simpson, Iain

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074531	A1	20030912	WO 2003-GB875	20030304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477125	A1	20030912	CA 2003-2477125	20030304
AU 2003209445	A1	20030916	AU 2003-209445	20030304
BR 2003008145	A	20041207	BR 2003-8145	20030304
EP 1483271	A1	20041208	EP 2003-743418	20030304
EP 1483271	B1	20061122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1639167	A	20050713	CN 2003-805124	20030304
CN 1307183	C	20070328		
JP 2005524669	T	20050818	JP 2003-572999	20030304
NZ 534684	A	20060224	NZ 2003-534684	20030304
AT 346072	T	20061215	AT 2003-743418	20030304
ES 2276092	T3	20070616	ES 2003-743418	20030304
ZA 2004006685	A	20051031	ZA 2004-6685	20040823
US 20050131052	A1	20050616	US 2004-506746	20040903
US 7122567	B2	20061017		
MX 2004PA08611	A	20041206	MX 2004-PA8611	20040906
NO 2004004033	A	20041125	NO 2004-4033	20040924
HK 1070365	A1	20070427	HK 2005-103055	20050411

PRIORITY APPLN. INFO.: GB 2002-5170 A 20020306
WO 2003-GB875 W 20030304

OTHER SOURCE(S): MARPAT 139:246010

GI



I



II

AB Heterocyclic amides of formula I (most examples are N-indenyl 4H-thieno[3,2-b]pyrrole-5-carboxamides, e.g. 2,3-dichloro-N-[(1R*,2R*)-1- (formylamino)-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5- carboxamide (shown as II)) (Z is CH or N; R4 and R5 together are either -SC(R6):C(R7)- or -C(R7):C(R6)S-; R6 and R7 = for example H, halo, C1-4alkyl, and C1-4alkanoyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R1 = for example halo, nitro, cyano, hydroxy, carboxy; r is 1 or 2; Y is -NR2R3 or -OR3; R2 and R3 = for example H, hydroxy, aryl, heterocyclyl and C1-4alkyl ((un)substituted by 1 or 2 R8 groups); R4 = for example H, halo, nitro, cyano, hydroxy, C1-4alkyl, and C1-4alkanoyl; R8 = for example hydroxy, -COCOOR9, -C(O)N(R9)(R10), -NHC(O)R9, (R9)(R10)N- and -COOR9 ; R9 and R10 = for example H, hydroxy, C1-4alkyl ((un)substituted by 1 or 2 R13); R13 = hydroxy, halo, trihalomethyl and C1-4alkoxy) or a pharmaceutically acceptable salt or pro-drug thereof are claimed; they possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity (e.g. type 2 diabetes, insulin resistance, syndrome X, hyperinsulinemia, hyperglucagonemia, cardiac ischemia, obesity). Processes for the manufacture of said heterocyclic amide derivs. and pharmaceutical compns. containing them are described. Inhibitory activity (IC50) of I in the direction of glycogen synthesis and on glycogen degradation were measure and are generally 100 μM to 1 nM; 4.5 μM for 2,3-dichloro-N-[(1S*,2S*)-1-[(3-thienylcarbonyl)amino]-2,3-dihydro-1H- inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide in the latter assay. Sixty-four example prepns. and/or characterization data for I and 23 for intermediates are included. For example, to prepare 2,3-dichloro-N- [(1R*,2R*)-1-(formylamino)-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2- b]pyrrole-5-carboxamide, N-((1R*,2R*)-1-amino-2,3-dihydro-1H-inden-2-yl)- 2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide trifluoroacetate (0.5 mmol), formic acid (1.4 mmol), DIPEA (1.0 mmol) and HOBT (0.5 mmol) were dissolved in CH2Cl2 (5 mL), stirred for 5 min, EDCI (0.625 mmol) added and the reaction stirred for 1 h; formic acid (1.4 mmol) and EDCI (1.25 mmol) were added, the reaction stirred for 2 h and the volatiles removed by evaporation under reduced pressure; workup gave 89% of the product as a white foam. The carboxamide reactant was prepared (82 %) by deprotection of 2,3-dichloro-5-[N-[(1R*,2R*)-1-[[N-(1,1-dimethylethoxy)carbonyl]amino]inda n-2-yl]carbamoyl]-4H-thieno[3,2-b]pyrrole using trifluoroacetic acid and this reactant was prepared (80 %) from 5-carboxy-2,3-dichloro-4H-thieno[3,2- b]pyrrole (preparation given) and trans-2-amino-1-[[(1,1- dimethylethoxy)carbonyl]amino]indan (preparation given) using DIPEA, HOBT in CH2Cl2 followed by EDCI.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:719447 HCAPLUS Full-text
DOCUMENT NUMBER: 139:245895
TITLE: Preparation of indolamide derivatives that possess glycogen phosphorylase inhibitory activity
INVENTOR(S): Whittamore, Paul Robert Owen; Bennett, Stuart Norman Lile; Simpson, Iain
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074484	A1	20030912	WO 2003-GB883	20030304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477717	A1	20030912	CA 2003-2477717	20030304
AU 2003216988	A1	20030916	AU 2003-216988	20030304
BR 2003008144	A	20041207	BR 2003-8144	20030304
EP 1483240	A1	20041208	EP 2003-712310	20030304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1639120	A	20050713	CN 2003-805309	20030304
CN 100374420	C	20080312		
JP 2005524667	T	20050818	JP 2003-572954	20030304
NZ 534683	A	20060224	NZ 2003-534683	20030304
IN 2004DN02324	A	20050401	IN 2004-DN2324	20040810
ZA 2004006681	A	20050922	ZA 2004-6681	20040823
US 20050107362	A1	20050519	US 2004-506554	20040901
US 7138415	B2	20061121		
MX 2004PA08612	A	20041206	MX 2004-PA8612	20040906
NO 2004004032	A	20041005	NO 2004-4032	20040924
PRIORITY APPLN. INFO.:			GB 2002-5176 A	20020306
			WO 2003-GB883 W	20030304

OTHER SOURCE(S): MARPAT 139:245895
GI



I

AB Heterocyclic amides of formula (I; 5-chloro-2-[N-(1-hydroxyindan-2-yl)carbamoyl]indole; A is phenylene or heteroarylene; m is 0, 1 or 2; n is 0, 1 or 2; R1 = for example halo, nitro, cyano, hydroxy, carboxy; r is 1 or 2; Y is -NR2R3 or -OR3; R2 and R3 = for example H, hydroxy, aryl, heterocyclyl and C1-4 alkyl((un)substituted by 1 or 2 R8 groups); R4 = for example H, halo, nitro, cyano, hydroxy, C1-4 alkyl, and C1-4 alkanoyl; R8 = for example hydroxy, -COCOOR9, -C(O)N(R9)(R10), -NHC(O)R9 , (R9)(R10)N- and -COOR9; R9 and R10 = for example H, hydroxy, C1-4 alkyl((un)substituted by 1 or 2 R13); R13 = hydroxy, halo, trihalomethyl and C1-4 alkoxy) or a pharmaceutically acceptable salt or prodrug thereof are claimed. They possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity, e.g. type 2 diabetes, insulin resistance, syndrome X, hyperinsulinemia, hyperglucagonemia, cardiac ischemia, obesity. Inhibitory activity (IC50) of I in the direction of glycogen synthesis and on glycogen degradation were measure and are generally 100 μM to 1 nM; 7.4 μM for 5-chloro-N-[(1R,2R)-1-[[[(2- hydroxyethyl)(phenylmethyl)amino]acetyl]amino]-2,3-dihydro-1H-inden-2-yl]- 1H-indole-2-carboxamide in the latter assay. Processes for the manufacture of said heterocyclic amide derivs. and pharmaceutical compns. containing them are described. Thirty-seven example prepns. and/or characterization data for I and 11 for intermediates are included. For example, to prepare 5-chloro-2-[N-(trans-1-hydroxyindan-2-yl)carbamoyl]indole, 5-chloro-1H-indole-2-carboxylic acid (0.67 mmol) was dissolved in CH2Cl2 (10 mL) containing DIPEA (1.19 mmol) and trans-2-aminoindan-1-ol (0.67 mmol) and HATU (0.67 mmol); the reaction mixture was stirred at room temperature for .apprx.18 h; workup gave 100 % of the desired compound To prepare trans-2-aminoindan-1-ol, isoamyl nitrite (108 mmol) was added to a solution of indan-1,2-dione (90 mmol) in MeOH (380 mL) at 45° followed by concentrated HCl (12 mL) dropwise over 5 min; the reaction mixture was stirred for 3 h at room temperature; workup gave indan-1,2-dione-2-oxime (43%), which (39 mmol) in EtOH (470 mL) and 4M HCl/dioxane (36 mL) was hydrogenated at room temperature and 40 psi; workup gave 86 % of the trans-2-aminoindan-1-ol.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> D HIS FUL

     FILE 'REGISTRY' ENTERED AT 14:44:16 ON 30 SEP 2008
L27             STR L25
L29         116 SEA SSS FUL L27

     FILE 'HCAPLUS' ENTERED AT 15:47:22 ON 30 SEP 2008
L33           4 SEA ABB=ON  PLU=ON  L29
                D STAT QUE L33
                D IBIB ABS HITSTR L33 1-4
L34          48 SEA ABB=ON  PLU=ON  ("BIRCH ALAN"/AU OR "BIRCH ALAN M"/AU OR
                "BIRCH ALAN MARTIN"/AU) OR BIRCH A/AU
L35         165 SEA ABB=ON  PLU=ON  BENNETT S/AU OR BENNETT S L/AU OR BENNETT
                S N/AU OR BENNETT STUART/AU OR BENNETT STUART N?/AU OR BENNETT
                NORMAN/AU OR BENNETT NORMAN L/AU OR STUART N/AU OR STUART
                NORMAN/AU
L36         144 SEA ABB=ON  PLU=ON  "CAMPBELL ANDREW"/AU OR "CAMPBELL ANDREW
                D"/AU OR "CAMPBELL ANDREW DUNCAN"/AU OR CAMPBELL A D/AU
L37         182 SEA ABB=ON  PLU=ON  SIMPSON I/AU OR SIMPSON I ?/AU OR "SIMPSON
                IAIN"/AU OR SIMPSON IAIN ?/AU
L38          31 SEA ABB=ON  PLU=ON  ("WHITTAMORE PAUL"/AU OR "WHITTAMORE PAUL
                R"/AU OR "WHITTAMORE PAUL R O"/AU OR "WHITTAMORE PAUL ROBERT
                OWEN"/AU)
L39          12 SEA ABB=ON  PLU=ON  "WHALLEY D"/AU OR ("WHALLEY DAVE P"/AU OR
                "WHALLEY DAVID"/AU) OR ("WHALLEY DAVID P"/AU OR "WHALLEY DAVID
                PAUL"/AU)
L40          47 SEA ABB=ON  PLU=ON  ("GODFREY LINDA"/AU OR "GODFREY LINDA
                V"/AU) OR GODFREY L/AU OR GODFREY L ?/AU
L41          10 SEA ABB=ON  PLU=ON  L34 AND (L35 OR L36 OR L37 OR L38 OR L39
                OR L40)
L42           9 SEA ABB=ON  PLU=ON  L35 AND (L36 OR L37 OR L38 OR L39 OR L40)
L43           1 SEA ABB=ON  PLU=ON  L36 AND (L37 OR L38 OR L39 OR L40)
L44           9 SEA ABB=ON  PLU=ON  L37 AND (L38 OR L39 OR L40)
L45           4 SEA ABB=ON  PLU=ON  L38 AND (L39 OR L40)
L46           2 SEA ABB=ON  PLU=ON  L39 AND L40
L47          13 SEA ABB=ON  PLU=ON  (L41 OR L42 OR L43 OR L44 OR L45 OR L46)
                NOT L33
                D STAT QUE L47
                D IBIB ABS HITSTR L47 1-13


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   29 SEP 2008  HIGHEST RN 1055027-88-7
     DICTIONARY FILE UPDATES:  29 SEP 2008  HIGHEST RN 1055027-88-7

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
```

predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE HCAPLUS

FILE COVERS 1907 - 30 Sep 2008 VOL 149 ISS 14
FILE LAST UPDATED: 29 Sep 2008 (20080929/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>